Basel, Switzerland
Scailyte, founded in 2017 and headquartered in Basel, Switzerland, is a leader in AI-driven biomarker discovery from single-cell omics data. The company’s proprietary AI platform, ScaiVision, enables the analysis of over 60 million single-cell profiles. This capability positions Scailyte at the forefront of developing precision medicine solutions.
With a strong focus on oncology and auto-immunity, the organization collaborates closely with an extensive network of clinical partners and biopharmaceutical companies. These collaborations have resulted in the development of multiple patent-pending biomarker signatures, showcasing the potential for biomarker-driven drug development.
The company operates in the AI, Biotechnology, and Healthcare industries and recently secured an $800.00K grant investment as of 01 March 2025. This funding supports its mission to make precision medicine a tangible reality.
